Treatment-nave , HCV genotype-1 patients were randomized to receive filibuvir 300 or 600 mg twice daily ( BID ) or placebo plus pegIFN ( 180 g/wk ) and ribavirin ( 1,000 / 1,200 mg BID ) for 24 weeks .